Levocetirizine in clinical practice of allergist

Levocetirizine is an effective H1-blocker of histamine receptors in complex treatment of various allergic diseases. The article presents the literature data and own observational data on clinical efficacy and safety of levocetirizine in the treatment of allergic diseases such as allergic rhinitis, bronchial asthma, allergic dermatoses.

Download Full-text

ОЦЕНКА ЦИТОКИНОВОГО ПРОФИЛЯ СЫВОРОТКИ КРОВИ И СУБПОПУЛЯЦИЙ Т-ЛИМФОЦИТОВ У ДЕТЕЙ С АЛЛЕРГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ ОРГАНОВ ДЫХАНИЯ

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/raj.2019.3.40502 ◽

2019 ◽

pp. 52-60

Author(s):

E.V. Prosekova ◽

A.I. Turyanskaya ◽

N.G. Plekhova ◽

M.S. Dolgopolov ◽

V.A. Sabynych

Keyword(s):

Allergic Rhinitis ◽

Bronchial Asthma ◽

Allergic Inflammation ◽

Allergic Diseases ◽

Control Group ◽

Healthy Children ◽

Serum Cytokine ◽

Immunological Parameters ◽

Low Level ◽

Level Of Significance

Расширение спектра изучаемых клонов Тхелперов определило более сложные иммунные механизмы реализации аллергического воспаления. Цель. Характеристика показателей и взаимосвязей цитокинового профиля сыворотки и субпопуляционного состава Тлимфоцитов периферической крови у детей с бронхиальной астмой и аллергическим ринитом. Материалы и методы. Проведено комплексное обследование 150 детей в возрасте 311 лет с верифицированным диагнозом бронхиальной астмы, аллергического ринита и 30 здоровых сверстников. Иммунологические параметры крови оценивали методом проточной цитометрии, концентрации интерлейкинов и IgE в сыворотке крови определяли методом твердофазного иммуноферментного анализа. При статистической обработке использовали программы Statistica 10 с критическим уровнем значимости р0,05. Результаты. У детей с аллергическими заболеваниями в сыворотке крови определены высокие уровни содержания интерлейкинов4, 8, 13, 17А, сопоставимый с показателями группы контроля уровень IL17F и низкое содержание IFNy. При бронхиальной астме и аллергическом рините у детей выявлено увеличение количества CD3CD8CD45RO, CD3CD8CD45RACD45RO Тлимфоцитов и CD3CD4 Тхелперов и повышение количество Th17 при снижении CD3CD4CD45RO клеток памяти. В группе здоровых детей популяция Th17 составляла 9,491,6, у детей с аллергическими заболеваниями количество данных клеток было значимо выше 14,50,77 (р0,001). Анализ сывороточного содержания цитокинов у детей с изолированным течением БА и в сочетании с аллергическим ринитом выявил разнонаправленные корреляции, отличающиеся по силе и направленности от таковых в группе здоровых детей. Заключение. У детей при изолированном течении бронхиальной астмы и в сочетании с аллергическим ринитом выявлены: сопоставимое с показателями здоровых детей количество CD3CD4 Тклеток, дисбаланс в субпопуляционном составе Тхелперов за счет преобладания Th2 и Th17, активация синтеза IL17A, IL4, IL8, IL13, низкий уровень сывороточного IFNy, изменения силы и направленности взаимосвязей цитокинового профиля и спектра субпопуляций Тлимфоцитов.Expansion of the range of examined Thelper clones has determined more complex immune mechanisms for the implementation of allergic inflammation. Objective. To characterize the parameters and relationships between the serum cytokine profile and Tlymphocyte subpopulation in peripheral blood of children with bronchial asthma and allergic rhinitis. Materials and methods. 150 children aged between 311 years old with bronchial asthma, and allergic rhinitis and 30 healthy volunteers were examined. Immunological parameters were assessed by flow cytometry, the concentration of serum interleukins and IgE were determined by means of enzymelinked immunosorbent assay. Statistical analysis was performed with Statistica 10 program with a critical level of significance p0.05. Results. High levels of interleukins 4, 8, 13, 17A were determined, IL7F level was not significantly different from that in control group and low level of IFNy was found in the serum of children with allergic diseases. The number of CD3CD8CD45RO, CD3CD8CD45RACD45RO Tlymphocytes, CD3CD4 Thelper cells and Th17 were increased and at the same time CD3CD4CD45RO memory cells were decreased In bronchial asthma and allergic rhinitis children. Number of Th17 cells in healthy children was 9.491.6, in allergic children it was significantly higher 14.50.77 (p0.001). Analyses of serum cytokine count in children with isolated BA and in association with allergic rhinitis revealed multidirectional correlations differing in strength and direction from those in the group of healthy children. Conclusion. In children with isolated bronchial asthma and associated with allergic rhinitis the following parameters were found: CD3CD4 Tcells count was comparable to that in healthy children, the imbalance of Thelper subpopulation: prevalence of Th2 and Th17, activation of IL17A, IL4, IL8, IL13 synthesis and low level of serum IFNy.

Download Full-text

APPLICATION OF VITAMIN D IN DIFFERENT DOSAGE TO TREAT CHILDREN WITH ALLERGIC DISEASES

Wiadomości Lekarskie ◽

10.36740/wlek202007114 ◽

2020 ◽

Vol 73 (7) ◽

pp. 1377-1383

Author(s):

Olexandra V. Tiazhka ◽

Zoriana V. Selska

Keyword(s):

Allergic Rhinitis ◽

Atopic Dermatitis ◽

Blood Serum ◽

Bronchial Asthma ◽

Vitamin D3 ◽

Allergic Diseases ◽

Acute Disease ◽

Disease Remission ◽

Significant Difference ◽

Different Doses

The aim: To study the dynamics of the level of 25(ОН)D, ІL-4, ІL-10, and IgG in the blood serum of children with allergic diseases and to study the clinical effect of vitamin D3 administration n different dosage in this category of patients. Materials and methods: 153 children aged 3-16 with such allergic diseases as bronchial asthma, atopic dermatitis and allergic rhinitis have been examined. The level of 25(ОН) D was determined using the electrochemiluminescence method, while the levels of ІL-4, ІL-10 and IgG were assessed using enzyme-linked immunoassay. Results: In the contrasting of the initial level of 25(ОН)D in the blood serum of patients after administration of 2,000 IU of vitamin D3 over 2 months, after summer and after treatment with cholecalciferol in higher doses (4,000–5,000 IU) over 2 months, significant difference was established between the indicators by the Friedman criterion (λ2 = 41.211; P < 0.05). In the similar contrasting of ІL-4 indicators, a significant difference between them was traced (P < 0.05) in the period of acute disease as well as the downward tendency in the period of remission. In the similar contrasting of ІL-10 indicators, a significant difference between them was traced (P < 0.05) in the acute period and in the period of disease remission. In the similar contrasting of IgG indicators, a downward tendency was traced in the period of acute disease and significant decrease (P < 0.05) – in the period of disease remission. In the contrasting of 25(ОН)D and ІL-4, ІL-10 figures a strong reverse correlation relationship was traced. The therapeutic effect of the administration of vitamin D3 medication in different doses in children with allergic diseases was traced. Conclusions: The data obtained shows that in the treatment of children with bronchial asthma, allergic rhinitis and atopic dermatitis the complex therapy should include vitamin D3 medications in different doses within a long-term course of treatment.

Download Full-text

Modern aspects of treatment of allergic rhinitis

Medical Council ◽

10.21518/2079-701x-2019-8-54-59 ◽

2019 ◽

pp. 54-59

Author(s):

D. V. Shabanov ◽

V. N. Fedoseeva

Keyword(s):

Developing Countries ◽

Allergic Rhinitis ◽

Clinical Practice ◽

Rural Population ◽

Inflammatory Process ◽

Adult Population ◽

Allergic Diseases ◽

2Nd Generation ◽

The World ◽

Regions Of Russia

The importance of allergic diseases is due to their increasing prevalence in both developed and developing countries. The prevalence of allergic diseases in most countries of the world is 10–30% among urban and rural population. In the regions of Russia, the prevalence of allergic diseases reaches 19–40% among the adult population and over 27% among children and adolescents. The article deals with the main aspects of the pathogenesis of allergic rhinitis as the most common allergic pathology. The features of antihistamine therapy with modern drugs of the 2nd generation and their influence on the links of the inflammatory process are considered. The data of studies of the effectiveness and safety of the original drug bilastine. Given the use cases bilastine in clinical practice.

Download Full-text

Place of levocetirizine in the treatment of allergic rhinitis

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja162 ◽

2018 ◽

Vol 15 (2) ◽

pp. 42-47

Author(s):

E F Glushkova ◽

N V Shartanova

Keyword(s):

Allergic Rhinitis ◽

Allergic Inflammation ◽

Allergic Diseases ◽

Complex Treatment

Levocetirizine is an effective Hj-blocker in complex treatment of various allergic patients. Allergic rhinitis is often part of a systemic allergic inflammation associated with other allergic diseases, therefore systemic antihistamines are the drugs of choice in it’s treatment.

Download Full-text

The Role of Interleukin-37 in the Pathogenesis of Allergic Diseases

Acta Naturae ◽

10.32607/20758251-2019-11-4-54-64 ◽

2019 ◽

Vol 11 (4) ◽

pp. 54-64

Author(s):

I. P. Shilovskiy ◽

M. E. Dyneva ◽

O. M. Kurbacheva ◽

D. A. Kudlay ◽

M. R. Khaitov

Keyword(s):

Allergic Rhinitis ◽

Atopic Dermatitis ◽

Bronchial Asthma ◽

Interleukin 1 ◽

Allergic Diseases ◽

Biological Properties ◽

Negative Regulator ◽

Cellular Mechanisms ◽

Wide Range

Cytokines of the interleukin-1 (IL-1) family play an important role in the realization of the protective functions of innate immunity and are the key mediators involved in the pathogenesis of a wide range of diseases, including various manifestations of allergy. The IL-1 family includes more than 11 members. However, the functions of many of them remain to be elucidated. Recently, new members of the IL-1 family have been discovered. In 2000, several independent research groups reported the discovery of a new interleukin of this family, which was named IL-37, or IL-1F7 (according to the new nomenclature). IL-37 was assigned to the IL-1 family based on its structural similarity with other members of this family. The study of its biological properties showed that its activity changes in inflammatory diseases, such as rheumatoid arthritis, psoriasis, as well as allergic diseases (allergic rhinitis, bronchial asthma, and atopic dermatitis). However, unlike most members of the IL-1 family, IL-37 acts as a negative regulator of inflammation. Activation of IL-37 suppresses inflammation, resulting in the suppression of inflammatory cytokines and chemokines, which in turn prevents infiltration of pro-inflammatory cells, mainly eosinophils and neutrophils. The exact molecular and cellular mechanisms of the anti-inflammatory effect of IL-37 in the development of allergic diseases (AD) have not been fully studied. This review summarizes and analyzes the accumulated experimental data on the role of IL-37 in the pathogenesis of AD, such as allergic rhinitis, bronchial asthma, and atopic dermatitis.

Download Full-text

Effectiveness of leukotriene receptor antagonists in the treatment for atopic pathology in children

Health and Ecology Issues ◽

10.51523/2708-6011.2020-17-4-10 ◽

2020 ◽

pp. 38-42

Author(s):

A. I. Zariankina ◽

M. Kh. Mirrakhimova ◽

E. R. Shamsieva

Keyword(s):

Allergic Rhinitis ◽

Atopic Dermatitis ◽

Bronchial Asthma ◽

Eosinophil Count ◽

Allergic Diseases ◽

Receptor Antagonists ◽

Leukotriene Receptor Antagonists ◽

Leukotriene Receptor

Objective: to study the effectiveness of leukotriene receptor antagonists in the treatment foratopic pathology in children.Material and methods. 224 children with allergic diseases were prescribed to take montelucast for 3– 6 months.Results. Taking montelucast has lead to positive clinical dynamics in 75 % of the cases.A significant reduction of the eosinophil count was achieved on days 10–15 of the therapy. The Cys-LTC4/D4/E4 indices came to normal after a one-month course of montelucast therapy in 40.3 % of cases in children with bronchial asthma, in 63.3 % of cases in children with allergic rhinitis and in 60.5 % of cases in children with atopic dermatitis.Conclusions. The use of montelucast has significantly enhanced the control incidencerate ofallergic diseases in children.

Download Full-text

An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data

Obstetrics Gynecology and Reproduction ◽

10.17749/2313-7347/ob.gyn.rep.2021.212 ◽

2021 ◽

Vol 15 (1) ◽

pp. 5-21

Author(s):

D. P. Kamilova ◽

M. M. Ovchinnikova ◽

E. Sh. Ablyaeva ◽

M. M. Leviashvili ◽

N. S. Stuleva ◽

...

Keyword(s):

Clinical Trials ◽

Clinical Practice ◽

Observational Study ◽

Clinical Efficacy ◽

Real World ◽

Ovarian Stimulation ◽

Successful Implementation ◽

Efficacy And Safety ◽

The Real ◽

Real Clinical Practice

Introduction. The efficacy and safety of biosimilar follitropin alpha have been demonstrated in randomized blinded prospective clinical trials of phases I and III. Unfortunately, there is a gap between the clinical trials and real clinical practice data. The real-world patient data helps to create an evidence-based background for successful implementation of medicine at everyday practice in a nonselected population.Aim: to investigate the efficacy of follitropin alpha biosimilar therapy (Primapur®) in nonselected real-world population.Materials and Methods. A retrospective observational anonymized cohort study of follitropin alpha biosimilar (Primapur®) as a pre-filled pen injector with a dose adjustment of 5 IU, aimed to investigate its efficacy and safety in a nonselected population with indications to assisted reproductive technologies (ART) was carried out. The ovarian stimulation (OS) protocols included: monotherapy protocols with using only Primapur®; mixed protocols (recombinant and urinary-derived gonadotropins); short protocols with using antagonists of gonadotropin-releasing hormone (GnRH) and long protocols with GnRH agonists. The stimulation protocols were analyzed with Primapur® application for at least 5 days.Results. The overall clinical efficacy of ovarian stimulation cycles (N = 5484) was: oocytes retrieved - 9.5 ± 7.2, mature (MII) - 6.8 ± 6.6, fertilized (2PN) - 6.1 ± 5.8, clinical pregnancy per ET (PR) - 38.4 %. Mixed gonadotropin protocols (N = 2625) vs. monotherapy with Primapur® (N = 2859): oocytes retrieved - 8.6 ± 6.8 vs. 10.3 ± 7.4 (p < 0.001), mature (MII) - 6.7 ± 6.2 vs. 7.7 ± 6.9 (p < 0.001), fertilized (2PN) - 5.8 ± 5.2 vs. 7.2 ± 6.2 (p < 0.001). There were statistically significant differences between oocyte yields in mixed vs. monotherapy protocols due to subgroup differences, including age, body mass index (BMI) and IVF/ICSI attempts. No statistically significant differences were found for PR: 39.3 % vs. 37.6 % (p = 0.314). Monotherapy protocols with GnRH antagonist OS (N = 2183) vs. GnRH agonist (N = 676) revealed: oocytes retrieved - 10.5 ± 7.5 vs. 9.6 ± 7.0 (p = 0.032), mature (MII) - 7.6 ± 6.9 vs. 6.7 ± 5.7 (p < 0.001), fertilized (2PN) - 7.3 ± 6.3 vs. 5.7 ± 5.0 (p < 0.001). There were statistically significant differences between BMI and IVF/ICSI attempts. No statistically significant differences were found for PR: 37.9 % vs. 35.9 % (p = 0.482). All medicines were well tolerated and no serious adverse reactions were reported.Conclusion. This was the largest retrospective observational study conducted in the field of fertility in Russia and involved 5484 ovarian stimulation protocols at 35 IVF clinics. The obtained results demonstrated similar clinical efficacy for follitropin alpha biosimilar Primapur® in different OS protocols in real clinical practice.

Download Full-text

Efficacy and safety of the antileukotriene drugs: relevant data. RAACI experts conclusion

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja1395 ◽

2020 ◽

Vol 17 (3) ◽

pp. 121-129

Author(s):

Natalya I. Il`ina ◽

Oksana M. Kurbacheva ◽

Natalya M. Nenasheva ◽

Natalya G. Astafieva ◽

Evgenij K. Beltyukov ◽

...

Keyword(s):

Allergic Rhinitis ◽

Adverse Events ◽

Bronchial Asthma ◽

Drug Administration ◽

Expert Opinion ◽

Adverse Reactions ◽

Efficacy And Safety ◽

The World ◽

Adults And Children ◽

Expert Commission

In many countries of the world and in Russia, in particular, the pharmacological use of antagonists of cysteinyl receptors LT1 (CysLTR) is a long-proven and well-proven pharmacotherapy of bronchial asthma (BA) and allergic rhinitis (AR) in adults and children. Among antileukotriene drugs the most commonly used medication for the treatment of these diseases is the original montelukast, which is considered a safe drug associated with the appearance of only a few adverse reactions, usually not differing in type and frequency from those that occur with placebo. Currently, there are a large number of generics of montelukast, therefore, practitioners have many questions regarding the benefits and risks of montelukast therapy for patients with BA and AR. In 2020 FDA (Food and Drug Administration USA) analyzed the risk of adverse events during Montelukast treatment and indicated them on the packaging of the drug (original montelukast and its generics). This contributed to the creation of an expert commission to study this issue and form an expert opinion, which is demonstrated in our publication.

Download Full-text